Vertex to Present New Data on JOURNAVX® Pain Management

Pharmaceutical company to showcase results of new aesthetic and surgical pain treatment.

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Vertex Pharmaceuticals, a leading biopharmaceutical company, announced it will present new data on its JOURNAVX® pain management treatment at an upcoming medical conference. The data is expected to demonstrate the effectiveness of JOURNAVX® in managing pain following aesthetic and surgical procedures.

Why it matters

Pain management is a critical aspect of post-operative and post-procedure care. Effective non-opioid pain treatments like JOURNAVX® can help reduce reliance on potentially addictive painkillers and improve patient recovery and satisfaction.

The details

JOURNAVX® is a novel non-opioid pain medication developed by Vertex Pharmaceuticals. The new data the company plans to present will highlight JOURNAVX®'s ability to effectively manage pain in patients undergoing aesthetic procedures like cosmetic surgery as well as various surgical operations.

  • The data presentation is scheduled for an upcoming medical conference in Boston, Massachusetts.

The players

Vertex Pharmaceuticals

A leading biopharmaceutical company that develops innovative treatments, including JOURNAVX®, a non-opioid pain medication.

Got photos? Submit your photos here. ›

The takeaway

The new JOURNAVX® data could provide healthcare providers with a promising non-opioid option to effectively manage pain and improve patient outcomes following aesthetic and surgical procedures.